CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc $(BCYC)$ has announced the issuance of inducement awards under its 2024 Inducement Plan, as approved by the Compensation Committee. On June 2, 2025, the company granted non-qualified share options to seven new employees, allowing them to purchase a total of 57,700 ordinary shares. These options come with an exercise price of $8.22 per share, corresponding to Bicycle Therapeutics' closing trading price on May 30, 2025. The vesting schedule spans four years, with 25% of the shares vesting one year after the vesting commencement date and the remainder vesting monthly over the subsequent 36 months, contingent upon continued employment with the company. These awards comply with Nasdaq Listing Rule 5635(c)(4).
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。